Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
Summary
Third Opinion Trial Synopsis:
Doctors want to see if giving two kinds of medicine, lenalidomide and ixazomib, together can help people who still have multiple myeloma after a stem cell transplant. Lenalidomide can help stop this cancer from growing or make it smaller, and ixazomib can also stop the cancer cells from growing by blocking certain enzymes. They think these medicines might work better together than just using one.
Doctors want to see if giving two kinds of medicine, lenalidomide and ixazomib, together can help people who still have multiple myeloma after a stem cell transplant. Lenalidomide can help stop this cancer from growing or make it smaller, and ixazomib can also stop the cancer cells from growing by blocking certain enzymes. They think these medicines might work better together than just using one.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplantation.
This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplantation.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: